Viral Vector Supply Chain
& AAV Gene Therapy Procurement

End-to-end supply chain solutions specifically designed for the unique complexity
of AAV gene therapy manufacturing: from plasmid and helper virus sourcing through CDMO selection, clinical supply planning, and commercial launch.

End-to-End Solutions Reliable Viral Vector Supply from Development to Commercialization

DES Pharma provides end-to-end supply chain solutions designed to ensure reliable, cost-effective AAV gene therapy drug product supply. From early development to commercial launch, we create supply strategies tailored to your viral vector program’s unique requirements, including the highly specialized raw materials, constrained CDMO landscape, and complex cold chain logistics specific to gene therapy.

Gene therapy supply chains differ fundamentally from small molecule and even standard biologic supply. Low production yields, limited qualified suppliers for critical materials, and small patient populations require a purpose-built strategy, not a generic pharmaceutical supply chain model.

🧪

Viral Vector-Specific Raw Material Sourcing

Specialized procurement capabilities for AAV gene therapy manufacturing materials

This includes plasmids (transgene, rep/cap, helper plasmid), helper virus systems (adenovirus, baculovirus components), and chromatography resins (AAVX, AVB Sepharose, AEX/CEX resins for AAV purification). We manage the entire supplier qualification and quality agreement lifecycle for gene therapy raw materials.

🚀 Plasmid Manufacturing & QC (transgene, rep/cap)
🚀 Helper Virus / Baculovirus System Sourcing
🚀 Affinity Chromatography Resins (AAVX, AVB)
🚀 Cell Culture Media & Sera (animal-free)
🚀 Single-Use Bioprocess Materials
🚀 Cryopreservation & Fill-Finish Materials
🚀 CDMO / CMO Selection & Qualification
🚀 Cold Chain Logistics (-80°C, LN2)

Proven Expertise Our Core Viral Vector
Supply Chain Services

Comprehensive procurement and supply chain management services built around the specific requirements of AAV gene therapy and viral vector manufacturing.

Raw Material Planning & Risk Assessment

Bill of materials analysis, safety stock strategy, and AAV-specific critical material qualification

Drug Product Supply Planning

Clinical demand forecasting, capacity allocation, and end-to-end supply chain map for AAV drug product

Contract Manufacturer (CDMO) Selection for AAV

RFP management, technical due diligence, and CDMO qualification for viral vector manufacturing

Product Storage & Biorepository Management

Cold chain strategy, warehouse management, and 3PL solutions for AAV gene therapy products

 

Contract Negotiations & Alliance Management

Vendor contract setup, cost modeling, and KPI governance for CDMO partnerships

Gene Therapy Supply Chain Expertise Navigating the Unique Complexity of Viral Vector Supply

AAV gene therapy supply chains are fundamentally different from conventional biologics. The limited landscape of qualified AAV CDMOs, the complexity of multi-plasmid raw material systems, ultra-low temperature cold chain requirements, and the need for chain-of-identity in autologous programs create challenges that standard pharmaceutical supply chain frameworks are not equipped to address.

DES Pharma has built our viral vector supply chain practice around these unique realities. We understand the critical path dependencies between plasmid delivery, CDMO slot availability, and clinical trial enrollment. We build supply strategies that protect programs from the common failure modes that delay gene therapy programs by months or years.

Whether you’re selecting your first CDMO partner, navigating a platform technology transfer, or building commercial supply chain infrastructure ahead of a BLA submission, DES Pharma delivers the specialized expertise and industry relationships to execute.

Critical Raw Material Risk Management

Single-source supplier identification, dual-sourcing strategy, safety stock models, and supply disruption contingency plans for GMP plasmids and chromatography resins

Ultra-Low Temperature Cold Chain Design

-80°C and liquid nitrogen supply chain design, validated shipping containers, qualified 3PL networks, and stability protocol alignment for gene therapy products

CDMO Selection & Technical Due Diligence

Structured AAV CDMO assessment across platform capabilities, GMP compliance, regulatory inspection history, and slot availability for your development timeline

Demand Planning for Rare Disease Programs

Small-batch clinical supply planning, patient registry-based enrollment forecasting, and commercial yield-adjusted demand models for ultra-orphan gene therapies

Viral Vector Raw Material Risk Framework Key Material Risk Categories
for AAV Manufacturing

Understanding the supply risk profile of your critical starting materials is the
foundation of a resilient viral vector supply chain strategy.

Raw Material Supply Complexity Lead Time DES Pharma Strategy
GMP Plasmids (transgene, rep/cap, helper) HIGH 12–20 weeks Early vendor qualification, dual-sourcing, rolling safety stock
Affinity Resins (AAVX, AVB Sepharose) HIGH 8–16 weeks Lifetime studies, resin reuse qualification, alternative resin validation
Serum-Free Cell Culture Media MEDIUM 4–8 weeks Lot-to-lot qualification, safety stock, chemically defined alternatives
Single-Use Bioprocess Components MEDIUM 4–12 weeks Leachables/extractables qualification, validated alternatives
Baculovirus / Helper Virus Systems HIGH 16–24 weeks In-house generation capability assessment, MCB/WCB backup strategy
Cryoprotectants & Formulation Excipients LOW 2–4 weeks Standard compendial sourcing with CoA review and supplier qualification

Our Approach Tailored Solutions, Immediate Impact

Three core principles that differentiate DES Pharma’s supply chain practice for gene therapy and biologics programs.

Customized Process

We listen, discuss, and understand your program's specific needs, applying our industry knowledge and CDMO network to deliver a rapid, customized viral vector supply strategy from development to commercialization.

Forward-Thinking Experts

Innovation is central to how we work. Our team of high-performing professionals provides access to the right skills and industry relationships for your gene therapy program's specific supply chain needs.

Immediate Value

We create immediate value through robust process implementation, optimizing cost, quality, and supply reliability, protecting your clinical timeline and commercial launch trajectory.

Get Started Build a Resilient Viral
Vector Supply Chain Today

Protect your AAV gene therapy program from supply disruptions and CDMO delays.